Combination Therapy May Offer Better Outcomes for Patients with Retinoblastoma
LOS ANGELES--(BUSINESS WIRE)--Researchers at The Saban Research Institute of Children’s Hospital Los Angeles (CHLA) have demonstrated that targeting survivin – a protein that inhibits apoptosis or cell death – enhances the effectiveness of chemotherapy in cells and mouse models of retinoblastoma (Rb), the most common malignant tumor of the eye in children. The study – led by Charles Gomer, PhD, of the Children's Center for Cancer and Blood Diseases at CHLA and Jonathan Kim, MD, director of the
